Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07939295
PHASE1/PHASE2

Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study

Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.

View on ClinicalTrials.gov

Summary

Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.

Official title: A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of KL002 Injection in the Striatal Putamen Region for Patients With Mid-to-Late Stage Primary Parkinson's Disease

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2027-01

Completion Date

2029-10

Last Updated

2026-11-16

Healthy Volunteers

No

Interventions

GENETIC

Injecting KL002 into the bilateral putamen

KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes

Locations (1)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, China